Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
N/A
Address
107 Rundle Street Kent Town, South Australia (SA) 5067
Description
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. It operates through the following segments: Faster Growing (iTrack), Emerging (2RT), and Core Ophthalmic Mark (Lasers and Ultrasounds). The iTrack segment offers catheter device that dilates the ocular structures compromised by glaucoma. The 2RT segment includes patent-protected with significant lead on competition and a per-use recurring fee business model. The Lasers and Ultrasounds segment represents testimony to the strength of the Ellex brand and was driven by growth in sales of the high-margin Ellex Tango and Ellex Tango Reflex glaucoma lasers. The company was founded by Giuseppe Canala and Victor Previn in 1985 and is headquartered in Kent Town, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.12 - 0.3
Trade Value (12mth)
AU$21,342.00
1 week
-3.85%
1 month
-26.47%
YTD
-28.57%
1 year
-37.5%
All time high
0.71
EPS 3 yr Growth
46.10%
EBITDA Margin
-25.60%
Operating Cashflow
-$8m
Free Cash Flow Return
-32.00%
ROIC
-36.40%
Interest Coverage
-85.40
Quick Ratio
1.80
Shares on Issue (Fully Dilluted)
229m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
14 February 25 |
Notice of General Meeting/Proxy Form
×
Notice of General Meeting/Proxy Form |
11 February 25 |
Change in substantial shareholding from AEF
×
Change in substantial shareholding from AEF |
07 February 25 |
Cleansing Notice
×
Cleansing Notice |
07 February 25 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
31 January 25 |
Quarterly Report 4C and Revenue guidance update
×
Quarterly Report 4C and Revenue guidance update |
31 January 25 |
EYE Completes $6.6 million placement
×
EYE Completes $6.6 million placement |
31 January 25 |
Investor Presentation
×
Investor Presentation |
31 January 25 |
Proposed issue of securities - EYE
×
Proposed issue of securities - EYE |
29 January 25 |
Trading Halt
×
Trading Halt |
17 December 24 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
28 November 24 |
Notification regarding unquoted securities - EYE
×
Notification regarding unquoted securities - EYE |
28 November 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
27 November 24 |
Notification of cessation of securities - EYE
×
Notification of cessation of securities - EYE |
27 November 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
21 November 24 |
2024 AGM presentation
×
2024 AGM presentation |
21 November 24 |
2024 AGM Voting Results
×
2024 AGM Voting Results |
31 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
18 October 24 |
Notice of AGM
×
Notice of AGM |
27 September 24 |
2024 AGM date and closing date for Director Nominations
×
2024 AGM date and closing date for Director Nominations |
26 August 24 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
26 August 24 |
Full Year Financial Results
×
Full Year Financial Results |
26 August 24 |
Investor Presentation 30 June 2024 Results
×
Investor Presentation 30 June 2024 Results |
26 August 24 |
Appendix 4G
×
Appendix 4G |
23 August 24 |
Notification of cessation of securities - EYE
×
Notification of cessation of securities - EYE |
02 August 24 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.